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Abstract
Background: The limited availability of prevalence data based on a representative sample of the general population, and
the limited number of diseases considered in studies about co-morbidity are the critical factors in study of autoimmune
diseases. This paper describes the prevalence of 12 autoimmune diseases in a representative sample of the general
population in the South of Sardinia, Italy, and tests the hypothesis of an overall association among these diseases.
Methods: Data were obtained from 21 GPs. The sample included 25,885 people. Prevalence data were expressed with 95%
Poisson C.I. The hypothesis of an overall association between autoimmune diseases was tested by evaluating the co-
occurrence within individuals.
Results: Prevalence per 100,000 are: 552 rheumatoid arthritis, 124 ulcerative colitis, 15 Crohn’s disease, 464 type 1 diabetes,
81 systemic lupus erythematosus, 124 celiac disease, 35 myasthenia gravis, 939 psoriasis/psoriatic arthritis, 35 systemic
sclerosis, 224 multiple sclerosis, 31 Sjogren’s syndrome, and 2,619 autoimmune thyroiditis . An overall association between
autoimmune disorders was highlighted.
Conclusions: The comparisons with prevalence reported in current literature do not show outlier values, except possibly for
a few diseases like celiac disease and myasthenia gravis. People already affected by a first autoimmune disease have a
higher probability of being affected by a second autoimmune disorder. In the present study, the sample size, together with
the low overall prevalence of autoimmune diseases in the population, did not allow us to examine which diseases are most
frequently associated with other autoimmune diseases. However, this paper makes available an adequate control
population for future clinical studies aimed at exploring the co-morbidity of specific pairs of autoimmune diseases.
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Introduction
The continued surveillance of autoimmune diseases contributes
greatly to the study of their aetiology and temporal trends, and to
the understanding of the relationship among these disorders. Such
[1]. Several studies on the epidemiology of autoimmune diseases
performed within the past several decades are discussed in a recent
review that highlights the importance of future studies that could
address limitations identified in the current literature [1].
The critical factor in studying the prevalence of autoimmune
diseases is the availability of a systematic and unbiased source of
data that are representative of the general population [1]. Routine
registration systems, like death statistics and hospital admission
and discharges, provide only a partial picture of the prevalence of
autoimmune diseases, because these diseases are characterized by
a low fatality and hospitality [1]. Collection of data through
population-based studies is the most suitable method for obtaining
prevalence data without ascertainment problems, though these
studies require considerable resources, in fact they are often based
on self reported data. However, in the case of autoimmune
diseases, which include rare diseases and diseases with consider-
able clinical heterogeneity and complex case definitions, the
collection of data through self reporting involves a high probability
of referral bias [1–3]. The few studies performed on the general
population are based on laboratory screening and consequently
focus only on autoimmune diseases detectable through laboratory
tests [11,17,18]. Additionally, their results include asymptomatic
forms of disease.
The limited availability of prevalence data based on a
representative sample of the general population is a possible
reason for the lack of definite evidence on the co-morbidity of
autoimmune disorders [1,2,3,4]. Several studies support the
hypothesis that there is a common aetiology for autoimmune
diseases. These studies usually assess the prevalence of a second
autoimmune disease in samples of patients already suffering from a
first one and compare these prevalence data with those of the
patients’ spouses or first degree relatives. A higher susceptibility to
a second autoimmune disease is regarded as an indication of
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diseases. The main limitation of these studies is the lack of an
adequate control population [3]. The prevalence obtained in
spousal or familial controls is based on self reported data that may
be affected by several biases (e.g. gender, age, educational level,
and confusion between diseases with similar names). In addition,
the design of these studies allows the evaluation of the co-
morbidity of three or four diseases at most. This limit is due to the
limited number of patients who already have an autoimmune
disorder and the low frequency of concomitant autoimmune
diseases. The limited number of diseases considered in studies
about co-morbidity makes it difficult to evaluate the hypothesis
that there is an overall association between autoimmune diseases
[1,4].
This paper aims to contribute to the study of autoimmune
diseases through three specific objectives. First, we describe the
prevalence of the main autoimmune diseases in a representative
sample of the general population in the South of Sardinia, Italy.
Next, we assess gender differences in prevalence of autoimmune
diseases. Last, we test the hypothesis of an overall association
among the main autoimmune diseases.
Methods
Study design
The design of this study is based on the Italian National Health
System (INHS), which makes the General practitioners (GPs) a
potential source of data for epidemiological studies.
The INHS covers the entire resident population, irrespective of
social status or pre-existing health conditions, and provides each
citizen with the service of a GP free of charge. Each citizen is
required by law to choose one GP from a list of at the Local
Health Agency. The choice of GP is mainly influenced by the
proximity of the GP’s office to the citizen’s place of residence
rather than by the citizen’s health status. GPs provide primary
care, prescribe pharmaceuticals and diagnostic procedures, and
refer patients to specialists and hospitals. Drugs for chronic
diseases are given free of charge by the INHS, provided that they
are prescribed by the GP. According to Italian law, a GP can
prescribe a drug ‘‘ free of charge’’ for a chronic disease only if the
diagnosis is performed and certified by INHS specialist. As a result
of this system, GPs are the main source of healthcare in Italy.
This study was carried out by the Department of Public Health
of the University of Cagliari-Italy, in collaboration with 21 GPs
who are members of the ‘‘Italian Society of General Medicine’’
(SIMG).
Each GP involved in the research had recorded patient data for
at least one decade using the software ‘‘Millewin’’. There is no
reasonable reason to suppose that people followed by these GPs
have health status different from that of the people followed by
GPs who do not register data with millewin. The diagnoses of
autoimmune diseases were performed by INHS specialists with
residency in different specific medical fields, and then entered
into the database by the GPs. entered into the database only after
the confirmation of the diagnosis by an INHS specialist. The
validity of diagnosis is guaranteed by specialists’ daily clinical
practice in public health system, adherence to National Pro-
grammes on Clinical Guidelines and Continuing Medical Educa-
tion programmes.
The Millewin software aims to make easily available to the GP
the main clinical data crucial for the care management, and offers
the following features as recording data (e.g. demographics
characteristics, ICD-IX diagnosis codes, ongoing therapy, pre-
scribed medications, adverse reactions, diagnostics, requests of
various kinds), management of drugs prescription, and an update
version of the Regional Therapeutic Formulary. This study
focused on a selected group of 12 diseases with chronic course
and a certain autoimmune component and that, also for
unanimous consensus among researchers and GPs, could be
characterized by well defined shared diagnostic criteria.
The syntax for extracting data from software Millewin, set up
by researchers and GPs, included demographic data and data
on the following diseases: rheumatoid arthritis (ICD-9: 714.0/00),
ulcerative colitis (ICD-9: 556.9/00), Crohn’s disease (ICD-9:
555.9/00), type 1 diabetes (ICD-9: 250.01/00), systemic lupus
erythematosus (ICD-9: 710.0/00), celiac disease (ICD-9: 579.0/
00), myasthenia gravis (ICD-9: 358.0/00), psoriasis/psoriatic
arthritis (ICD-9: 696.1/00, 696.0/00), systemic sclerosis (ICD-9:
710.1/00), multiple sclerosis (ICD-9: 340.0/00), Sjogren’s syn-
drome (ICD-9: 710.2/00), and autoimmune thyroiditis (ICD-9:
245.2/00).
Sample
The survey was performed in 2009 in Sardinia, Italy, which
is a Mediterranean island with a population of 1,671,000
inhabitants.
Data collection covered a representative sample of the southern
part of the regional territory, provinces of Cagliari and Carbonia-
Iglesias with 700,000 inhabitants, and included the metropolitan
area of Cagliari, the 2 urban towns of Carbonia and Iglesias, and
the 3 semi-urban villages of Narcao, Masainas, and Sant’Anna
Arresi. The metropolitan area of Cagliari accounts for half of the
population, the urban towns accounts for 30% of the population,
and the small villages for the 20%. The considered sample covers
proportionally the three different settlements of the southern part
of the region, thus preventing the possibility of a systematic error
regarding to the characteristics of the people included in the
sample. In fact 10 out of 21 GPs are from the metropolitan area, 7
are from the urban towns, and 4 from the semi-urban villages. The
research focused on those individuals who were between 15 and 89
years old. Children under 15 years of age were excluded because
they are normally treated by paediatricians. The data were
extracted, in July 2009, by each GP from his or her personal
database, cleared of identifying information (that were substitute
with a code created taking into account the first letter of name and
surname, the place and date of birth, the sex, the place of
residence), and provided to the researchers.
The sample included 25,885 people, 14, 167 of whom were
women and 11,718 of whom were men.
Statistical analysis
Prevalence data were expressed as cases per 100,000 popula-
tion, and 95% confidence intervals were calculated according to
the Poisson distribution. The total number of people between 15
and 89 years of age registered with GPs involved in this study was
used as denominator for prevalence.
Gender differences in the prevalence of autoimmune diseases
are examined using Fisher Chi square test.
The hypothesis that there is an overall association between the
autoimmune diseases was tested by evaluating the co-occurrence
of autoimmune diseases within individuals. The observed and
expected numbers of people with zero, one, or more than one co-
occurring autoimmune diseases were compared using Chi square
test.
The number of expected cases was calculated, on the basis of
the prevalence values of each disease according to the formulae
described below.
Prevalence and Comorbidity of Autoimmune Diseases
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has been defined as the product of the probabilities of not
having each examined disease. It is calculated as:
P0~P 1{pi ðÞ
where pi is the prevalence of each examined disease.
– The probability of having only one autoimmune disease, (P1),
has been defined as the sum of the products of the probability
of having each specific disease and the probabilities of not
having the other diseases. It is calculated as:
P1~
X
pi~x P 1{pi=x
    
1{px ðÞ
  
where pi=x is the prevalence of a specific disease, whereas pi?x is
the prevalence of the other diseases.
– The probability of having more than one autoimmune disease,
(P.1), is estimated as:
Pw1~1{P0{P1
Results
Table 1 shows the population distribution according to the
presence or the absence of autoimmune diseases. Overall, the
prevalence of autoimmune diseases was 5.0% with a 95%
confidence interval of 4.7%–5.3%. More specifically, among the
1,300 people with autoimmune diseases, 95.6% were affected by
one autoimmune disorder while the remaining 4.4% were affected
by two autoimmune disorders. Among women the prevalence of
people with autoimmune disorder was 6,9% . Among the 981
females with autoimmune diseases 95.2% were affected by one
autoimmune disorder, whereas the remaining 4.8% were affected
by two autoimmune disorders. Among men the prevalence of
people with autoimmune disorder was slightly higher than it was
among women (2,8%). Among men with autoimmune diseases,
96.9% were affected by one autoimmune disorder, whereas the
remaining 3.1% were affected by two autoimmune disorders.
The prevalence of each autoimmune disease is shown in
Table 2. The highest prevalence was observed for autoimmune
thyroiditis. Myasthenia gravis, systemic sclerosis, Sjogren’s syn-
drome and Crohn’s disease were the least frequent diseases. The
prevalence of autoimmune disease according to gender is reported
in Table 3. Among women, the highest prevalence value was
observed for autoimmune thyroiditis, followed by psoriasis/
psoriatic arthritis, rheumatoid arthritis, type 1 diabetes and
multiple sclerosis. Among men, the highest prevalence was
observed for psoriasis/psoriatic arthritis, followed by type 1
diabetes, autoimmune thyroiditis and rheumatoid arthritis.
The prevalence values of autoimmune thyroiditis, rheumatoid
arthritis, multiple sclerosis, celiac disease and systemic lupus
erythematosus were significantly higher among women than
among men. The prevalence of psoriasis/psoriatic arthritis was
significantly higher among men than among women. The
prevalence of the other autoimmune diseases was not significantly
different between men and women.
Data about the co-morbidity of autoimmune diseases are shown
in Table 4. The statistical analysis of the co-morbidity of
autoimmune diseases highlights the fact that the number of
people with more than one autoimmune diseases was significantly
higher than the number expected under the null hypothesis that
there is no association between autoimmune disorders. This
finding was confirmed both in women and men. In order to verify
whether the higher than expected number of people with more
than one autoimmune diseases was only due to the high frequency
of autoimmune thyroiditis in the sample under investigation, the
analysis of co-morbidity was repeated excluding from the sample
those people who were affected by this disorder. This analysis still
indicated a significantly higher than expected number of people
with more than one autoimmune disorder (p,0.001).
Discussion
This paper contributes to the study of autoimmune diseases by
defining the prevalence of the most common autoimmune diseases
in a representative sample of the general population in South
Sardinia, Italy, and investigating the co-morbidity between
autoimmune disorders that affect different organs. To our
knowledge, this is the first population-based study that investigates
a consistent number of autoimmune diseases in a sample of the
general population [1]. Autoimmune diseases are complex
disorders caused by a combination of genetic susceptibility and
environmental factors [3,4,5]. The island of Sardinia provides an
Table 1. Absolute frequencies of people with zero, one, or
more than one autoimmune diseases.
Number of autoimmune diseases
01.1
TOTAL SAMPLE (N=25885) 24,585 1,243 57
WOMEN (N=14167) 13,186 934 47
MEN (N=11718) 11,399 309 10
doi:10.1371/journal.pone.0032487.t001
Table 2. Prevalence of each autoimmune disease per 100000
people.
Prevalence per 10
5 95% C.I.
Autoimmune thyroiditis 2,619 2426–2824
Psoriasis/psoriatic arthritis 939 824–1065
Rheumatoid arthritis 552 466–651
Type 1 diabetes 464 384–554
Multiple sclerosis 224 170–290
Ulcerative colitis 124 85–175
Celiac disease 124 85–175
Systemic lupus erythematosus 81 50–124
Myasthenia gravis 35 16–66
Systemic sclerosis 35 16–66
Sjogren’s syndrome 31 13–61
Crohn’s disease 15 4–40
doi:10.1371/journal.pone.0032487.t002
Prevalence and Comorbidity of Autoimmune Diseases
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32487ideal setting to investigate autoimmune diseases because of the
genetic background of its inhabitants, who appear to be prone to
these disorders [5,6].
The unbiased source of data is the main strength of this
research. Data were obtained from a database of 21 GPs who
systematically recorded their patient data for at least one decade,
and the appropriateness of each diagnosis was confirmed by a
specialist. Furthermore, the reliability of the data presented in this
paper can be confirmed by a comparison between the prevalence
of type 1 diabetes and multiple sclerosis as determined on the basis
of the data under investigation and the prevalences of these
diseases obtained in previous population based studies performed
in Sardinia [5,7,8]. According to the present research, the
prevalence of type 1 diabetes is 464 cases per 100,000 people
with a 95% C.I. ranging from 384 to 554. This estimate agrees
with that obtained in a previous study, which found a prevalence
of 459 cases per 100,000 people with a 95% C.I. ranging from 407
to 517 [5,8]. Similarly, the present data on the prevalence of
multiple sclerosis overlap with those estimated in a recent study,
performed in the south-western part of the regional territory,
which indicate a prevalence of 210 cases per 100,000 people with a
95% C.I. ranging from 168 to 234 [7].
This study showed that 5% of the general population is affected
by one or more autoimmune diseases. These results agree with the
data in the current literature that indicate an overall prevalence of
autoimmune diseases in the range of 4%–5% [9,10].
Overall, the prevalence was higher in women (7%) than in men
(3%), confirming the existing evidence [10,11].
According to our data, the autoimmune thyroiditis is the most
widespread autoimmune disease with a prevalence value that is a
reliable estimate of the symptomatic forms of disease, but it does
not cover all of the asymptomatic cases, because GPs usually only
investigate the presence of antithyroid-antibodies in people with
clinical symptoms or with a family background of this disease. This
prevalence is higher than what has been reported in hospital-based
study, and it is similar only to prevalence values obtained in the
United Kingdom [1,9,12].
Psoriasis/psoriatic arthritis and rheumatoid arthritis are the
next most common autoimmune disorders, and their prevalence
rates appear to be consistent with those reported in the current
literature [1,13,14].
The prevalence values for type 1 diabetes, and multiple sclerosis
confirm that Sardinia is among those regions with the highest
prevalence of these disorders [5,15].
The prevalence of ulcerative colitis, is lower than that observed
in a Danish hospital-based study, whereas it appears to agree with
the prevalence observed in Hungary [1,9,10,16]. The rate of celiac
disease is lower than the 7% prevalence observed in Italy through
a screening program, but is similar to the values observed in the
Danish hospital-based study and in a Greek study [9,10,17,18,19].
The prevalence of systemic lupus erythematosus is in line with
prevalence data reported for Italy [16]. The prevalence of
Myasthenia Gravis appears to be slightly higher than values
observed in other population based surveys, but in contrast to the
published literature, it is not different between men and women
[9,10,20,21,22,23]. The prevalence of systemic sclerosis similar to
values reported in the current literature for European countries
[9,10,24,25]. Similarly prevalence of Crohn’s disease, 15 cases per
100,000, is comparable to values observed in Bosnia and Hungary
[16,26]. The prevalence of Sjogren’s syndrome, 31 cases per
Table 3. Prevalence of autoimmune diseases according to gender.
WOMEN MEN p value
Prevalence per 10
5 95% C.I. Prevalence per 10
5 95% C.I.
Autoimmune thyroiditis 4376 4039–4735 495 376–640 ,0.001
Psoriasis/psoriatic arthritis 776 638–936 1135 950–1345 0.003
rheumatoid arthritis 741 606–897 324 229–445 ,0.001
Type 1 diabetes 424 323–545 512 391–659 0.31
Multiple sclerosis 296 214–401 137 78–222 0.008
Ulcerative colitis 127 75–201 119 65–200 .0.99
Celiac disease 212 143–302 17 22678 ,0.001
Systemic lupus erythematosus 148 92–227 0 0–31 ,0.005
Myasthenia gravis 42 16–92 26 5–75 0.53
Systemic sclerosis 56 24–111 9 0–48 0.05
Sjogren’s syndrome 42 16–92 17 22–62 0.31
Crohn’s disease 14 2–51 17 2–62 .0.99
doi:10.1371/journal.pone.0032487.t003
Table 4. Co-morbidity of autoimmune diseases: number of
observed and expected people with zero, one and more than
one autoimmune disease.
Number of
Autoimmune
Diseases
Number
Observed
Number
Expected p value
TOTAL SAMPLE 0 24,585 24,553 ,0.001
(N=25885) 1 1,243 1,308
.1 57 24
WOMEN 0 13,186 13,161 ,0.001
(N=14167) 1 934 983
.1 47 22
MEN 0 11,399 11,392 0.001
(N=11718) 1 309 322
.1 10 3
doi:10.1371/journal.pone.0032487.t004
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based study, but is lower than the value obtained in other
population based studies [9,10,27].
These data on the prevalence of each autoimmune disease are
valuable for the public health system, because they may allow an
accurate evaluation of the burden of the diseases. The particular
genetic background of the population under investigation suggests
caution in generalizing these results to a world-wide level. In any
case, these data provide a picture of the relative burden of the
studied diseases.
With regard to the co-occurrence of autoimmune diseases
within individuals, the present study highlights an overall
association between autoimmune disorders, both in women and
in men. According to our results, people already affected by a first
autoimmune disease have a higher probability of being affected
by a second autoimmune disorder. Our results agree with the
hypothesis that there is a potential common pathogenic mecha-
nism among autoimmune diseases [1,28]. In the present study, the
sample size, together with the low overall prevalence of
autoimmune diseases in the population, did not allow us to
examine which diseases are most frequently associated with other
autoimmune diseases. However, this paper indirectly contributes
to the achievement of this goal, because the data on the prevalence
of each autoimmune disease make available an adequate control
population for future clinical studies aimed at exploring the co-
morbidity of specific pairs of autoimmune diseases.
Finally, this survey confirms the potential role of GPs in disease
surveillance, offering an example of how a GPs’ databases can be
used for prevalence studies. To avoid the potential information
bias of this source of data, the full involvement of GPs from the
planning phase is the essential prerequisite because it guarantees
the accuracy and completeness of the diagnosis. In Italy, as in
several other countries, GPs are the main health care providers for
citizens, and therefore they could be a valuable source of data that
should be further explored [29,30,31].
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